9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 70

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events.,  Phase 2 – To evaluate the efficacy of autologous genetically modified TC-210 T cells in patients with MSLN-expressing unresectable, metastatic, or recurrent cancers as determined by overall response rate using RECIST v1.1,  ,

Interventions: TC-210 T Cells, fludarabine

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: June 2021

Completion Date: January 2023

Last  Posted Date: July 29, 2019

Location: National Cancer Institute, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT03907852

Was this article helpful?
Dislike 0